Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 2/2019

Open Access 01-02-2019

Predictors for INR-control in a well-managed warfarin treatment setting

Authors: Fredrik Björck, Hayder Kadhim, Anders Själander

Published in: Journal of Thrombosis and Thrombolysis | Issue 2/2019

Login to get access

Abstract

Warfarin is well studied in patients with non-valvular atrial fibrillation (AF). It has low complication rates for patients achieving individual Time in Therapeutic Range (iTTR) > 70%. The risk scores SAMe-TT2R2 and PROSPER are designed to predict future TTR, but are derived from a heterogeneous population with generally low iTTR. The aim of this study was to evaluate predictors for high and low iTTR in an AF population in Sweden, where there is a generally good anticoagulation control. A retrospective register study based on Swedish warfarin dosing system AuriculA, including 28,011 AF patients starting treatment during 1 January 2006 to 31 December 2011. Complications and risk factors were analysed and related to iTTR. Mean age was 73.7 (SD ± 9.5) years, with 42.0% women. Mean CHA2DS2-VASc score (SD) was 3.6 (± 1.7). For patients with iTTR < 60% there were over three times higher prevalence of excessive alcohol consumption than for patients with iTTR > 70% (3.7% vs. 1.1%). Previous stroke were more prevalent for patients with high than low iTTR (17.1% vs. 20.3%). Concomitant comorbidities were associated with increased risk of poor iTTR. In Swedish AF patients, excessive alcohol use is clearly associated with iTTR below 60%. Patients with previous stroke are more likely to get iTTR above 70%, unlike those with concomitant disorders who more often have poor anticoagulation control. The SAMe-TT2R2-score cannot be applied in Sweden.
Appendix
Available only for authorised users
Literature
2.
go back to reference Sjogren V, Grzymala-Lubanski B, Renlund H, Friberg L, Lip GY, Svensson PJ et al (2015) Safety and efficacy of well managed warfarin. A report from the Swedish quality register Auricula. Thromb Haemost 113:1370–1377CrossRefPubMed Sjogren V, Grzymala-Lubanski B, Renlund H, Friberg L, Lip GY, Svensson PJ et al (2015) Safety and efficacy of well managed warfarin. A report from the Swedish quality register Auricula. Thromb Haemost 113:1370–1377CrossRefPubMed
3.
go back to reference Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG et al (2010) Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 376:975–983CrossRef Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG et al (2010) Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 376:975–983CrossRef
4.
go back to reference Bjorck F, Renlund H, Lip GY, Wester P, Svensson PJ, Sjalander A (2016) Outcomes in a Warfarin-treated population with atrial fibrillation. JAMA Cardiol 1:172–180CrossRefPubMed Bjorck F, Renlund H, Lip GY, Wester P, Svensson PJ, Sjalander A (2016) Outcomes in a Warfarin-treated population with atrial fibrillation. JAMA Cardiol 1:172–180CrossRefPubMed
5.
go back to reference Apostolakis S, Sullivan RM, Olshansky B, Lip GY (2013) Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT(2)R(2) score. Chest 144:1555–1563CrossRefPubMed Apostolakis S, Sullivan RM, Olshansky B, Lip GY (2013) Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT(2)R(2) score. Chest 144:1555–1563CrossRefPubMed
6.
go back to reference Lin KJ, Singer DE, Glynn RJ, Blackley S, Zhou L, Liu J et al (2017) Prediction score for anticoagulation control quality among older adults. J Am Heart Assoc 6(10):e006814CrossRefPubMedPubMedCentral Lin KJ, Singer DE, Glynn RJ, Blackley S, Zhou L, Liu J et al (2017) Prediction score for anticoagulation control quality among older adults. J Am Heart Assoc 6(10):e006814CrossRefPubMedPubMedCentral
8.
go back to reference Grzymala-Lubanski B, Sjalander S, Renlund H, Svensson PJ, Sjalander A (2013) Computer aided warfarin dosing in the Swedish national quality registry AuriculA—algorithmic suggestions are performing better than manually changed doses. Thrombos Res 131:130–134CrossRef Grzymala-Lubanski B, Sjalander S, Renlund H, Svensson PJ, Sjalander A (2013) Computer aided warfarin dosing in the Swedish national quality registry AuriculA—algorithmic suggestions are performing better than manually changed doses. Thrombos Res 131:130–134CrossRef
11.
go back to reference Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E (1993) A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 69:236–239CrossRefPubMed Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E (1993) A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 69:236–239CrossRefPubMed
12.
go back to reference De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F et al (2013) Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis–Task Force on Anticoagulants in Heart Disease. Thromb Haemost 110:1087–1107CrossRefPubMed De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F et al (2013) Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis–Task Force on Anticoagulants in Heart Disease. Thromb Haemost 110:1087–1107CrossRefPubMed
13.
go back to reference Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY (2010) A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138:1093–1100CrossRefPubMed Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY (2010) A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138:1093–1100CrossRefPubMed
14.
go back to reference Singer DE, Hellkamp AS, Piccini JP, Mahaffey KW, Lokhnygina Y, Pan G et al (2013) Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. J Am Heart Assoc 2:e000067PubMedPubMedCentral Singer DE, Hellkamp AS, Piccini JP, Mahaffey KW, Lokhnygina Y, Pan G et al (2013) Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. J Am Heart Assoc 2:e000067PubMedPubMedCentral
15.
go back to reference Mukamal KJ, Tolstrup JS, Friberg J, Jensen G, Gronbaek M (2005) Alcohol consumption and risk of atrial fibrillation in men and women: the Copenhagen City Heart Study. Circulation 112:1736–1742CrossRefPubMed Mukamal KJ, Tolstrup JS, Friberg J, Jensen G, Gronbaek M (2005) Alcohol consumption and risk of atrial fibrillation in men and women: the Copenhagen City Heart Study. Circulation 112:1736–1742CrossRefPubMed
16.
go back to reference Al-Khalili F, Benson L, Friberg L (2018) Alcohol-related hospitalization is associated with increased risk of ischaemic stroke among low-risk patients with atrial fibrillation. Europace 20:19–24CrossRefPubMed Al-Khalili F, Benson L, Friberg L (2018) Alcohol-related hospitalization is associated with increased risk of ischaemic stroke among low-risk patients with atrial fibrillation. Europace 20:19–24CrossRefPubMed
Metadata
Title
Predictors for INR-control in a well-managed warfarin treatment setting
Authors
Fredrik Björck
Hayder Kadhim
Anders Själander
Publication date
01-02-2019
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 2/2019
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-018-1765-4

Other articles of this Issue 2/2019

Journal of Thrombosis and Thrombolysis 2/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.